Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 23,041

Document Document Title
WO/2019/073299A1
The present invention provides methods for the treatment of a central nervous system (CNS) tumor in a subject comprising administering and IL-4 targeted cargo protein formulated in an artificial cerebral spinal fluid formulation. The pre...  
WO/2019/073964A1
The present disclosure provides a technique whereby the influence of an endogenous TCR is eliminated in TCR gene transfer. A TCR gene is edited using a genome editing enzyme, said genome editing enzyme having one characteristic that amin...  
WO/2019/075200A1
The present disclosure provides a split intein selectable marker system for the production and selection of transgenic cells.  
WO/2019/071358A1
A trifunctional molecule comprising a target-specific ligand, a ligand that binds a protein associated with the TCR complex and a T cell receptor signaling domain polypeptide is provided. The ligand that binds a protein associated with a...  
WO/2019/075373A1
This document relates to methods and materials for gene editing. For example, methods and materials for using a RecA polypeptide fused to a cell penetrating peptide to edit (e.g., correct) a gene are provided.  
WO/2019/075098A1
The present disclosure provides ribonucleic acids that provide for translation stalling. The present disclosure provides ribosome/nucleic acid complexes comprising the ribonucleic acids, as well as ribosome/nucleic acid/nascent chain pol...  
WO/2019/075270A1
The present application provides an antibody fusion protein comprising a vascular endothelial growth factor receptor (VEGFR) fused to the C-terminus of the antibody light chain. Also provided are methods of making and using these antibod...  
WO/2019/071274A1
Compositions and methods for editing endogenous RNA molecules are provided.  
WO/2019/070577A1
Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-br...  
WO/2019/068066A1
The present invention relates to a method able to enhance survival and functionality of anti-tumor or anti-viral immune cells through overexpression of Akt molecules in the cells. Akt signaling prevented the expression of immune checkpoi...  
WO/2019/060980A1
Described herein are uses of fluorescent enveloped virus particles as standards in nanoscale flow cytometry applications. The virus particles comprise a fluorescent dye or a fluorescent protein. A standard ladder comprising a plurality o...  
WO/2019/067425A1
The present invention includes compositions and methods for treating heart disease and/or heart failure. In one embodiment, the treatment includes administering to the subject a cell genetically modified to express a chimeric antigen rec...  
WO/2019/067740A1
This disclosure relates to nanoparticles coated with fusion proteins comprising a domain that binds a cancer marker and a domain comprising a toxic polypeptide. In certain embodiments, the targeted cancer marker is urokinase plasminogen ...  
WO/2019/040920A8
The present invention relates to methods of preparing a therapeutic exosome using a protein newly-identified to be enriched on the surface of exosomes. Specifically, the present invention provides methods of using the proteins for affini...  
WO/2019/061962A1
Provided is an anti-interleukin-17A (IL-17A) antibody, a preparation method therefor and an application thereof. Specifically, said antibody is an anti-IL-17A monoclonal antibody. Said antibody can be combined in a highly specific way wi...  
WO/2019/061562A1
Provided is a new chimeric antigen receptor (CAR) molecule containing a DAP10 protein intracellular segment, and a nucleic acid for encoding same, a cell expressing same, and a use thereof in the preparation of a drug for treating tumors...  
WO/2019/062744A1
Using the characteristics of G-protein coupled receptors (GPCR) for sensing specific ligands and undergoing conformational change, inserting a signal molecule in an intracellular region of the G-protein coupled receptors, converting the ...  
WO/2019/062642A1
A double targeting fusion protein targeting PD-1 or PD-L1 and targeting VEGF family. Said double targeting fusion protein comprises (i) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (ii) a VID effectively linked at the C-terminus ...  
WO/2019/067770A1
Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine r...  
WO/2019/062790A1
Provided herein are novel conjugates and pharmaceutical compositions comprising the novel conjugate described herein. The use of the novel conjugate to inhibit the growth of cancer cells and induce antibody production in a subject in nee...  
WO/2019/066603A1
The present invention relates to a protein conjugate, in which a physiologically active polypeptide modified with a fatty acid molecule and an immunoglobulin Fc region are linked through a non-peptide polymer linker, a pharmaceutical com...  
WO/2019/057180A1
Provided are proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.  
WO/2018/208124A3
The present invention relates to a compound having a structure in which isotretinoin is linked to a peptide via a covalent bond and an antibiotic, anti-inflammatory, or anti-oxidative pharmaceutical or cosmetic composition comprising the...  
WO/2019/056106A1
The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to ...  
WO/2019/056099A1
Provided are humanized anti-HLA-A2 antibodies. In certain aspects, the humanized anti-HLA-A2 antibodies are capable of constituting an antigen binding domain of a chimeric antigen receptor (CAR), where the CAR is capable of being express...  
WO/2019/058289A1
The invention relates to peptide conjugates of Formula (I). The peptide conjugates of the invention have activity as MAIT agonists. The peptide conjugates of the invention also enhance immune responses and therefore are effective vaccine...  
WO/2019/057122A1
A polypeptide complex comprises antibody variable regions of the heavy chain and light chain respectively fused to TCR constant regions. A bispecific antigen binding polypeptide complex contains a first antigen-binding moiety of the poly...  
WO/2019/057087A1
Various molecular constructs having a plurality of fatty acids and functional elements are provided. Methods for treating various diseases using such molecular constructs are also disclosed.  
WO/2019/057181A1
Provided are compositions and methods for treating cancer comprising the use of aimmunoconjugate in combination with a cytotoxic agent or cytotoxic therapy. The immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy s...  
WO/2018/091544A8
The invention provides conjugates, comprising an organ or tissue targeting moiety linked to a biologically active moiety or linked to a diagnostic moiety. Such a biologically active or diagnostic moiety can be, for example, an oligonucle...  
WO/2019/051586A1
AXL-specific antibodies and uses therefor are described, including monoclonal and single domain antibodies. Such antibodies bind to cell surface expressed human AXL at an epitope in an immunoglobulin-like (IgL) domain of the AXL ectodoma...  
WO/2019/051954A1
Two long-acting recombinant porcine FSH (follicle-stimulating hormone) fusion proteins, comprising pFSH-Fc-1 and pFSH-Fc-2. α subunit/β subunit is directly or indirectly fused on an Fc fragment by means of a connecting component; the ...  
WO/2019/055955A1
Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence ("FCS"), whic...  
WO/2019/050998A1
The present disclosure relates to a method of targeting extracellular vesicles employing a molecule comprising a GLA domain and extracellular vesicles obtained or obtainable from a method disclosed herein.  
WO/2019/047299A1
Provided is a transdermal short peptide having nuclear positioning capability, the amino acid sequence thereof being as represented by SEQ ID No. 1; also provided is a fusion protein having nuclear positioning capability, comprising a ma...  
WO/2019/050036A1
The present invention provides: a peptide that includes a partial amino acid sequence of the C16orf74 protein, includes the cysteine at position 7 and/or the cysteine at position 14 of the C16orf74 protein, and inhibits dimer formation o...  
WO/2019/046943A1
Provided herein is a polypeptide encoding a modified collagen-like protein or fragment thereof, wherein the modified collagen-like protein comprises at least one of the following features: is more soluble in acidic, neutral, and/or basic...  
WO/2019/049144A1
Described herein are synthetic polypeptide inhibitors of the SET-domain-containing protein 6 (SETD6) methyltransferase, and polypeptide chimeras thereof including at least one cell penetrating peptide. Pharmaceutical compositions and use...  
WO/2019/050997A1
The present disclosure relates to a method of targeting stems cells, in particular non-apoptotic stem cells, employing a GLA domain, capable of binding surface exposed phosphatidyl serine.  
WO/2019/051002A1
The present disclosure relates to a method of intracellular delivery of a molecule employing a GLA domain to facilitate entry into the cell.  
WO/2019/049967A1
Disclosed is an aqueous pharmaceutical composition which comprises, as an active ingredient, a fused protein of an antibody with a lysosomal enzyme and has sufficient stability to enable the distribution thereof in the market. The aqueou...  
WO/2019/051501A1
Provided herein are methods and compositions relating to G protein-coupled receptor (GPCR) libraries having nucleic acids encoding for a scaffold comprising a GPCR binding domain. Libraries described herein include variegated libraries c...  
WO/2019/050948A1
The invention provides a recombinant RNA molecule comprising (i) a sequence of a gene-editing molecule mRNA, or a sequence of a functional fragment or derivative thereof, and (ii) at least one sequence of a coding or non-coding enrichmen...  
WO/2019/010222A3
Polynucleotides encoding immunostimulatory fusion molecules that include an immune cell targeting moiety and a cytokine molecule, pharmaceutical and formulations thereof, and methods of using and making the same, are disclosed.  
WO/2019/046577A1
Methods and compositions for making bacteriocins are described in some embodiments herein. In some embodiments, pro-polypeptide comprising the bacteriocins in the desired ratios in cis, and separated by cleavage sites can be produced by ...  
WO/2019/041036A1
Provided herein are polypeptide epitopes of aspartyl-(asparaginyl)-3-hydroxylase ("AABH") as well as polyepitopes thereof. Also provided are antibodies that specifically bind these polypeptide epitopes and poly epitopes, as well as bindi...  
WO/2019/044894A1
The present invention addresses the problem of providing a compound having strong conjugating activity with respect to a modified collagen, a use of the compound as a modified collagen test drug and research reagent, and a composition co...  
WO/2019/045075A1
To provide a therapeutic agent for endometriosis and adenomyosis. IL-33 was identified as an exacerbating factor in endometriosis and adenomyosis, and an IL-33 antagonist, which is capable of inhibiting the function of IL-33, was found t...  
WO/2019/046338A1
Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described that bind to an epitope on the ECL2 loop of human TM4SF1. Methods of use of said antibodies and fragments are also described, including for the inhibition of me...  
WO/2019/045025A1
Provided is a vaccine composition for treating or preventing a cancer with VASH2 expression, said vaccine composition containing a peptide which comprises the amino acid sequence represented by SEQ ID NO: 4.  

Matches 1 - 50 out of 23,041